- Home
- EDTK vs CELU Comparison
EDTK vs CELU Comparison
Compare EDTK & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | CELU |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | United States |
| Employees | N/A | 115 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDTK | CELU |
|---|---|---|
| Price | $0.91 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 1.8K | ★ 87.5K |
| Earning Date | 01-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.56 |
| 52 Week High | $1.18 | $4.30 |
Technical Indicators
Market Signals| Indicator | EDTK | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 41.17 |
| Support Level | $0.89 | $0.56 |
| Resistance Level | $1.03 | $0.85 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 4.76 | 28.44 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.